BELGIAN GUIDELINES FOR ECONOMIC EVALUATIONS: SECOND EDITION
The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Objectives:The aim of this study was to present the updated methodological guidelines for economic evaluations of healthcare interventions (drugs, medical devices, and other interventions) in Belgium. Methods:The update of the guidelines was performed by three Belgian health economists following feedback from users of the former guidelines and personal experience. The updated guidelines were discussed with a multidisciplinary team consisting of other health economists, assessors of reimbursement request files, representatives of Belgian databases and representatives of the drugs and medical devices industry. The final document was validated by three external validators that were not involved in the previous discussions. Results:The guidelines give methodological guidance for the following components of an economic evaluation: literature review, perspective of the evaluation, definition of the target population, choice of the comparator, analytic technique and study design, calculation of costs, valuation of outcomes, definition of the time horizon, modeling, handling uncertainty and discounting. We present a reference case that can be considered as the minimal requirement for Belgian economic evaluations of health interventions. Conclusions:These guidelines will improve the methodological quality, transparency and uniformity of the economic evaluations performed in Belgium. The guidelines will also provide support to the researchers and assessors performing or evaluating economic evaluations.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Decision Modelling For Health Economic Evaluation
Briggs, A., Claxton, K., & Sculpher, M. (2006) · doi:10.1093/oso/9780198526629.001.0001 · Cited by 3,153
External validity of randomised controlled trials: “To whom do the results of this trial apply?”
Rothwell, P. M. (2005) · The Lancet · doi:10.1016/s0140-6736(04)17670-8 · Cited by 2,544
Bucher, H. C., Guyatt, G. H., Griffith, L. E., & Walter, S. D. (1997) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(97)00049-8 · Cited by 2,052
Weinstein, M. C., O'Brien, B., Hornberger, J., Jackson, J., Johannesson, M., McCabe, C., & Luce, B. R. (2003) · Value in Health · doi:10.1046/j.1524-4733.2003.00234.x · Cited by 1,172
Song, F., Altman, D. G., Glenny, A.-M., & Deeks, J. J. (2003) · BMJ · doi:10.1136/bmj.326.7387.472 · Cited by 943
Caro, J. J., Briggs, A. H., Siebert, U., & Kuntz, K. M. (2012) · Value in Health · doi:10.1016/j.jval.2012.06.012 · Cited by 766 · cited 1×
“Guidelines for good general modeling practices (22;23) and for infectious disease modeling (24) ought to be followed whenever a model is built.”
BackgroundIndirect comparison meta-analysis of aspirin therapy after coronary surgery
Lim, E., Ali, Z., Ali, A., Routledge, T., Edmonds, L., Altman, D. G., & Large, S. (2003) · BMJ · doi:10.1136/bmj.327.7427.1309 · Cited by 84
Guidelines for Pharmacoeconomic Evaluations in Belgium
Cleemput, I., Wilder, P. V., Vrijens, F., Huybrechts, M., & Ramaekers, D. (2008) · doi:10.57598/r78c · Cited by 62
Self-citationA social preference valuations set for EQ-5D health states in Flanders, Belgium
Cleemput, I. (2009) · The European Journal of Health Economics · doi:10.1007/s10198-009-0167-0 · Cited by 53 · cited 1×
“If the EQ-5D is used, the Belgian (Flemish) tariff values should be applied (21).”
MethodSelf-citationEconomic Evaluation of Long Term Management Strategies for Erosive Oesophagitis
Goeree, R. A., Brien, B. O., Hunt, R. H., Blackhouse, G., Willan, A. R., & Watson, J. (1999) · PharmacoEconomics · doi:10.2165/00019053-199916060-00007 · Cited by 43 · cited 1×
“identification of all relevant treatments for the targeted indication and population, the removal of dominated or extendedly dominated interventions from the list of relevant comparators, and the calculation of the ICERs of all interventions compared with the next best alternative (13;14).”
Background
Research works printed but not linked: 6
- Gray, 2010, Applied methods of cost effectiveness analysis in healthcare. Handbooks in health economic evaluation, vol. 3
- Chapter III of the law of 14 July 1994 on the compulsory insurance of healthcare (B.S. - M.B. 27/08/1994). http://www.riziv.fgov.be/fr/publications/Pages/reglementation-medication.aspx (access date February 12, 2015).
- le Polain M , Franken M , Koopmanschap M , Cleemput I . Drug reimbursement systems: International comparison and policy recommendations. In: KCE Reports, vol. 147C. Belgian Health Care Knowledge Centre (KCE), Brussels, 2010. https://kce.fgov.be/publication/report/drug-reimbursement-systems-international-comparison-and-policy-recommendations-0 (accessed February 12, 2015).
- 2009, Working paper cost estimation
- Van De Sande S , De Wachter D , Swartenbroekx N , et al. Inventory of health care databases. In: KCE Reports, vol. 30B. Belgian Health Care Knowledge Centre (KCE), Brussels, 2006. https://kce.fgov.be/fr/publication/report/inventaire-des-bases-de-données-de-soins-de-santé (accessed February 12, 2015).
- 2006, Guidelines for pharmacoeconomic research, updated version
Cited by
Belgian population norms for the EQ-5D-5L, 2018
Wilder, L. V., Charafeddine, R., Beutels, P., Bruyndonckx, R., Cleemput, I., Demarest, S. S., Smedt, D. D., Hens, N., Scohy, A., Speybroeck, N., et al. (2021) · Quality of Life Research · doi:10.1007/s11136-021-02971-6 · Cited by 76
Self-citationAn EQ-5D-5L Value Set for Belgium
Bouckaert, N., Cleemput, I., Devriese, S., & Gerkens, S. (2022) · PharmacoEconomics - Open · doi:10.1007/s41669-022-00353-3 · Cited by 63
“Belgium is one of many countries to recommend the use of the EQ-5D to measure health-related quality of life (HRQoL) and to calculate quality-adjusted life years (QALYs) [1, 3].”
Self-citationWilder, L. V., Devleesschauwer, B., Clays, E., Buyser, S. L. D., der Heyden, J. V., Charafeddine, R., Boeckxstaens, P., Bacquer, D. D., Vandepitte, S., & Smedt, D. D. (2021) · Quality of Life Research · doi:10.1007/s11136-021-02951-w · Cited by 65
“HRQoL was measured using the EQ-5D-5L, the most widely used preference-based instrument for measuring HRQoL [21] and recommended by Belgian guidelines for economic evaluations in health care [27].”
MethodDeep Inspiration Breath Hold in Left-Sided Breast Radiotherapy
Busschaert, S.-L., Kimpe, E., Gevaert, T., Ridder, M. D., & Putman, K. D. (2024) · JACC CardioOncology · doi:10.1016/j.jaccao.2024.04.009 · Cited by 30
Debaveye, S., Smedt, D. D., Heirman, B., Kavanagh, S., & Dewulf, J. P. (2019) · BMC Health Services Research · doi:10.1186/s12913-019-4247-2 · Cited by 25
Metadata
- Authors
- Thiry, N., Neyt, M., Van De Sande, S., & Cleemput, I.
- Affiliations
- Belgian Health Care Knowledge Centre (KCE) (BE)
- Venue
- International Journal of Technology Assessment in Health Care
- Publisher
- Cambridge University Press (CUP)
- Published
- 2014-12
- Volume
- 30
- Issue
- 6
- Pages
- 601-607
- ISSN
- 0266-4623 (ISSN-L)
- 1471-6348
- OpenAlex
- W2319137882
- Cited by
- 23
- References
- 14
- Citations by year
- 2026: 6 · 2025: 2 · 2024: 5 · 2023: 1 · 2022: 3 · 2021: 2 · 2019: 2 · 2017: 1 · 2016: 1
- FWCI
- 1.66
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- International Journal of Technology Assessment in Health Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Social Sciences › Sociology and Political Science › Delphi Technique in Research
- Keywords
- economic evaluation guidelines, health interventions, reimbursement decision-making, cost-effectiveness analysis, target population definition, comparator selection, cost valuation, outcome valuation, time horizon, uncertainty analysis, discounting
- MeSH terms
- Belgium, Costs and Cost Analysis, Humans, Research Design, Technology Assessment, Biomedical, Guidelines as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: BELGIAN GUIDELINES FOR ECONOMIC EVALUATIONS: SECOND EDITION. https://app.cochat.ai/papers/10.1017/s0266462314000725
- The paper
- Thiry, N., Neyt, M., Van De Sande, S., & Cleemput, I. (2014). BELGIAN GUIDELINES FOR ECONOMIC EVALUATIONS: SECOND EDITION. International Journal of Technology Assessment in Health Care. https://doi.org/10.1017/s0266462314000725
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.